BTQ Technologies Announces Strategic Partnership with QPerfect to Achieve Quantum Advantage Using Neutral Atom Quantum Processors
BTQ Technologies and QPerfect have entered a strategic partnership to co-develop quantum-secure applications using neutral atom quantum computers, coinciding with QPerfect CEO Philippe Blot's participation in the France Quantum roundtable "How Emulators Can Accelerate Your Quantum Technology Adoption?", held under the High Patronage of President Emmanuel Macron and in the presence of French Minister for the Armed Forces, Sébastien Lecornu.
The partnership merges BTQ's cryptographic and quantum algorithms expertise with QPerfect's advanced emulation and error correction capabilities, aiming to deliver fault-tolerant quantum algorithms for quantum-secure transactions, one-shot signatures, smart contracts, decentralized identity, quantum money, and secure communications.
QPerfect will provide research resources and emulation tools, while BTQ will lead the quantum algorithm design and implementation of quantum-safe cryptographic protocols, with a formal implementation roadmap targeted by June 30, 2025.
VANCOUVER, BC, June 10, 2025 /CNW/ - BTQ Technologies Corp. (the "Company") (CBOE CA: BTQ) (FSE: NG3) (OTCQX: BTQQF), a global quantum technology company focused on securing mission-critical networks, is pleased to announce that it has entered into an agreement with QPerfect, a leading neutral atom quantum computing company based in Strasbourg, to redefine the future of secure digital transactions. This groundbreaking partnership will co-develop next-generation, post-quantum secure technologies powered by neutral atom quantum computers.
The collaboration combines BTQ's expertise in post-quantum cryptography and quantum algorithms with QPerfect's Quantum Logic Unit (QLU) —an accelerator for quantum error correction that translates high-level quantum circuits into highly optimized machine code tailored for neutral atom quantum processors.
QPerfect is a pioneering quantum computing startup specializing in quantum emulation, quantum software, and quantum error correction, with a focus on neutral atom architectures. By harnessing its modular QLU, QPerfect bridges the gap between quantum algorithm design and real hardware execution, empowering researchers, developers, and end-users to accelerate the realization of industry-transforming quantum applications. The company's flagship product, MIMIQ, is a cutting-edge emulation platform that delivers unmatched speed, accuracy, and flexibility for testing quantum algorithms, surpassing the capabilities of both traditional quantum simulators and today's quantum computers.
BTQ has pioneered research into quantum one-shot signatures — a quantum cryptographic primitive that will form the bedrock underlying secure quantum communication systems and the quantum internet. BTQ's work addresses critical vulnerabilities in digital transactions and blockchain systems by developing protocols that leverage self-destructing quantum keys and post-quantum secure verification mechanisms. The company's research team, comprising leading post-quantum cryptographers, has demonstrated practical applications of one-shot signatures in financial transactions, smart contracts, and decentralized identity management systems.
Key objectives of the collaboration include:
Joint design, development, and testing of practical quantum algorithms for quantum one-shot signatures, with a focus on efficient implementation on neutral atom hardware.
Co-development of fault-tolerant, hardware-specific approaches to quantum one-shot signatures and associated applications that prioritize minimal use of quantum resources.
Delivery of a blueprint and prototype for quantum one-shot signatures compatible with next-generation neutral atom quantum computers.
Defined Roles
Under the agreement, QPerfect will assemble a dedicated team of researchers and provide access to its leading quantum emulation tools, while BTQ will translate advanced cryptographic concepts into implementable quantum algorithms. Both parties will collaborate on project planning, patent applications, and scientific dissemination.
Leadership Commentary
Olivier Roussy Newton, CEO of BTQ Technologies, commented:
"We are thrilled to join forces to accelerate the development of quantum advantage using neutral atom quantum processors. By combining BTQ's strengths in post-quantum cryptography and one-shot signature technology with QPerfect's world-class expertise in quantum software and hardware, we are marking a key milestone to achieve quantum advantage, opening the door to a new generation of applications, including quantum-secure transactions, advanced crypto and e-money solutions, and the next-generation quantum communications. This partnership marks a significant step forward in our mission to deliver practical, industry-transforming quantum solutions for the digital era.."
Philippe Blot, CEO of QPerfect, added:
"Formalizing our partnership with BTQ marks a turning point in applied quantum cryptography. This collaboration reflects QPerfect's commitment to enabling powerful real-world quantum applications through modular, fault-tolerant architectures—tailored here for BTQ's unique vision."
Both parties aim to negotiate further implementation agreements by June 30, 2025.
About QPerfect
QPerfect is a French quantum computing company based in Strasbourg, specializing in quantum computing and quantum design automation. Founded in 2023, the deeptech company has received the i-Lab Grand Prix and provides powerful technology to enable researchers, developers, and manufacturers to realize the full potential of quantum computers.
At the core of QPerfect's innovation is the Quantum Logical Unit (QLU), a multi-layered framework designed to accelerate quantum development. Its flagship product, MIMIQ, forms the first layer of the QLU and offers a cutting-edge platform that executes quantum algorithms with unmatched speed, accuracy, and flexibility, surpassing existing simulators and current quantum computers. For more information, please visit https://qperfect.io
About BTQ
BTQ was founded by a group of post-quantum cryptographers with an interest in addressing the urgent security threat posed by large-scale universal quantum computers. With the support of leading research institutes and universities, BTQ is combining software and hardware to safeguard critical networks using unique post-quantum services and solutions.
Connect with BTQ: Website | LinkedIn
ON BEHALF OF THE BOARD OF DIRECTORS
Olivier Roussy Newton
CEO, Chairman
Neither Cboe Canada nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information
Certain statements herein contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Such forward-looking statements or information include but are not limited to statements or information with respect to the business plans of the Company, including with respect to its research partnerships, and anticipated markets in which the Company may be listing its common shares. Forward-looking statements or information often can be identified by the use of words such as "anticipate", "intend", "expect", "plan" or "may" and the variations of these words are intended to identify forward-looking statements and information.
The Company has made numerous assumptions including among other things, assumptions about general business and economic conditions, the development of post-quantum algorithms and quantum vulnerabilities, and the quantum computing industry generally. The foregoing list of assumptions is not exhaustive.
Although management of the Company believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that forward-looking statements or information herein will prove to be accurate. Forward-looking statements and information are based on assumptions and involve known and unknown risks which may cause actual results to be materially different from any future results, expressed or implied, by such forward-looking statements or information. These factors include risks relating to: the availability of financing for the Company; business and economic conditions in the post-quantum and encryption computing industries generally; the speculative nature of the Company's research and development programs; the supply and demand for labour and technological post-quantum and encryption technology; unanticipated events related to regulatory and licensing matters and environmental matters; changes in general economic conditions or conditions in the financial markets; changes in laws (including regulations respecting blockchains); risks related to the direct and indirect impact of COVID-19 including, but not limited to, its impact on general economic conditions, the ability to obtain financing as required, and causing potential delays to research and development activities; and other risk factors as detailed from time to time. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
9 hours ago
- Cision Canada
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan."This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Cision Canada
9 hours ago
- Cision Canada
Minco Capital Corp. Announces Voting Results of 2025 Annual General Meeting
VANCOUVER, BC, June 20, 2025 /CNW/ - Minco Capital Corp. (the "Company" or "Minco Capital") (TSXV: MMM) (OTCQX: MGHCF) (FSE: MI5) is pleased to announce the voting results of its Annual General Meeting of Shareholders held today in Vancouver, British Columbia (the "Meeting"). All matters set forth in the Management Information Circular dated May 14, 2024 (the "Information Circular") were approved by shareholders. The number of directors was set at three (3), and all director nominees were duly elected to serve until the next annual meeting of shareholders or until their successors are duly appointed. The results of the director elections were as follows: In addition, shareholders voted: 95.81% in favour of setting the number of directors at three, 99.94% in favour of appointing Smyth CPA LLP, Chartered Accountants as auditors for the ensuing year, and 95.68% in favour of authorizing the transaction of other business as described in the Information Circular. The detailed voting results are available in the Report of Voting Results filed on the Company's SEDAR+ profile on June 20, 2025. About Minco Capital: Minco Capital Corp. (TSXV: MMM / OTCQX: MGHCF / FSE: MI5) is a Canadian company focused on identifying high-quality investment opportunities, primarily in publicly traded and privately held corporations as well as direct ownership stakes in resource projects. The Company owns 11 million shares of Minco Silver Corporation. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cision Canada
9 hours ago
- Cision Canada
Minco Silver Announces Voting Results of 2025 Annual General Meeting of Shareholders
VANCOUVER, BC, June 20, 2025 /CNW/ - Minco Silver Corporation (the "Company" or "Minco Silver") (TSX: MSV) (OTCQX: MISVF) (WKN: A0ESX5) is pleased to announce the voting results of its 2025 Annual General Meeting of Shareholders held today in Vancouver, British Columbia (the "Meeting"). All matters outlined in the Company's Management Information Circular dated May 14, 2025 (the "Information Circular") were approved by shareholders. The number of directors was set at four (4), and all director nominees were duly elected to serve until the next annual meeting of shareholders or until their successors are appointed. The detailed voting results for the election of directors are as follows: Shareholders also approved the following resolutions: 99.95% in favour of setting the number of directors at four; 99.95% in favour of appointing MSLL CAP LLP, Chartered Accountants, as auditors for the ensuing year; and 99.93% in favour of transacting other business as described in the Information Circular. Detailed voting results are available in the Report of Voting Results filed under the Company's profile on SEDAR+ on June 20, 2025. About Minco Silver: Minco Silver Corporation (TSX: MSV / OTCQX: MISVF / WKN: A0ESX5) is a Canadian public company focused on the exploration and development of high-potential mineral resource projects. The Company's flagship assets include the Fuwan Silver Project and the Changkeng Gold Project, both located approximately 45 kilometres southwest of Guangzhou City, China. Minco Silver continues to evaluate and pursue new acquisition opportunities to enhance long-term shareholder value.
